ATE244014T1 - Verwendung von apoptose-induzierende mittel zur herstellung eines mittels zur behandlung von (auto)immunkrankheiten - Google Patents

Verwendung von apoptose-induzierende mittel zur herstellung eines mittels zur behandlung von (auto)immunkrankheiten

Info

Publication number
ATE244014T1
ATE244014T1 AT00900970T AT00900970T ATE244014T1 AT E244014 T1 ATE244014 T1 AT E244014T1 AT 00900970 T AT00900970 T AT 00900970T AT 00900970 T AT00900970 T AT 00900970T AT E244014 T1 ATE244014 T1 AT E244014T1
Authority
AT
Austria
Prior art keywords
auto
apoptosis
immune diseases
agent
producing
Prior art date
Application number
AT00900970T
Other languages
English (en)
Inventor
Mathieu Hubertus Mari Noteborn
Alexandra Maria Pietersen
Original Assignee
Leadd Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leadd Bv filed Critical Leadd Bv
Application granted granted Critical
Publication of ATE244014T1 publication Critical patent/ATE244014T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT00900970T 1999-01-11 2000-01-10 Verwendung von apoptose-induzierende mittel zur herstellung eines mittels zur behandlung von (auto)immunkrankheiten ATE244014T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99200056 1999-01-11
PCT/NL2000/000013 WO2000041497A2 (en) 1999-01-11 2000-01-10 Use of apoptosis inducing agents in the treatment of (auto)immune diseases

Publications (1)

Publication Number Publication Date
ATE244014T1 true ATE244014T1 (de) 2003-07-15

Family

ID=8239795

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00900970T ATE244014T1 (de) 1999-01-11 2000-01-10 Verwendung von apoptose-induzierende mittel zur herstellung eines mittels zur behandlung von (auto)immunkrankheiten

Country Status (18)

Country Link
US (1) US20050271624A1 (de)
EP (1) EP1143994B1 (de)
JP (1) JP2003500336A (de)
AT (1) ATE244014T1 (de)
AU (1) AU3083500A (de)
CA (1) CA2359392A1 (de)
DE (1) DE60003632T2 (de)
DK (1) DK1143994T3 (de)
EA (1) EA200100770A1 (de)
ES (1) ES2202039T3 (de)
HU (1) HUP0200552A2 (de)
IL (2) IL144228A0 (de)
MX (1) MXPA01006998A (de)
NO (1) NO20013397L (de)
PT (1) PT1143994E (de)
TR (1) TR200102713T2 (de)
WO (1) WO2000041497A2 (de)
ZA (1) ZA200105632B (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002079222A2 (en) * 2001-03-30 2002-10-10 Leadd B.V. Fusion proteins for specific treatment of cancer and auto-immune diseases
US6924266B2 (en) * 2001-05-25 2005-08-02 Nymox Corporation NTP-peptides and method for removal of tumors
PL207588B1 (pl) * 2001-07-19 2011-01-31 Nymox Corp Peptyd NTP, środek zawierający ten peptyd i zastosowanie tego peptydu
US7317077B2 (en) 2001-11-16 2008-01-08 Nymox Pharmaceutical Corporation Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670488A (en) * 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
US5981502A (en) * 1990-09-12 1999-11-09 Leadd B.V. Methods and compositions for inducing apoptosis in tumor cells
EP0878546A1 (de) * 1997-04-15 1998-11-18 Leadd B.V. Genabgabe-Vehikel die das Apoptosis VP2 inducierendes Protein, und/oder Apoptin exprimiert
US5792751A (en) * 1992-04-13 1998-08-11 Baylor College Of Medicine Tranformation of cells associated with fluid spaces
NZ309171A (en) * 1995-06-07 2000-04-28 Leadd Bv use of apoptin as an antitumour agent which specifically kills tumour and not normal cells
DE19704979A1 (de) * 1996-02-07 1997-08-14 Max Delbrueck Centrum Retroviraler Vektor für den Gentransfer eines IL6-Antagonisten in humane hämatopoetische Stammzellen
JP2001516210A (ja) * 1997-02-28 2001-09-25 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 遺伝子治療による炎症細胞の自己調節されたアポトーシス
JPH10324699A (ja) * 1997-03-21 1998-12-08 Sankyo Co Ltd 抗ヒトFasヒト化抗体
AU736287B2 (en) * 1997-03-21 2001-07-26 Sankyo Company Limited Humanized anti-human Fas antibody

Also Published As

Publication number Publication date
WO2000041497A2 (en) 2000-07-20
JP2003500336A (ja) 2003-01-07
HUP0200552A2 (en) 2002-06-29
DE60003632D1 (de) 2003-08-07
EA200100770A1 (ru) 2002-02-28
PT1143994E (pt) 2003-11-28
NO20013397L (no) 2001-09-11
ZA200105632B (en) 2002-10-09
TR200102713T2 (tr) 2002-05-21
IL144228A0 (en) 2002-05-23
EP1143994B1 (de) 2003-07-02
ES2202039T3 (es) 2004-04-01
EP1143994A2 (de) 2001-10-17
MXPA01006998A (es) 2002-05-06
AU3083500A (en) 2000-08-01
DE60003632T2 (de) 2004-04-15
IL144228A (en) 2009-06-15
NO20013397D0 (no) 2001-07-09
CA2359392A1 (en) 2000-07-20
US20050271624A1 (en) 2005-12-08
DK1143994T3 (da) 2003-10-20
WO2000041497A3 (en) 2000-09-28

Similar Documents

Publication Publication Date Title
CY1118979T1 (el) Αντισωματα που κατευθυνονται εναντι her-3 και χρησεις αυτων
TNSN08064A1 (en) Albumin fusion proteins
NZ502527A (en) Catalytic monoclonal antibodies raised to proteins in aggregated form, and use to treat alzheimers, atherosclerosis, amyloidosis and prions disease
DE60028970D1 (de) An her2 bindende peptidverbindungen
NO20064059L (no) Albumin fusjonsproteiner
HUP0103758A2 (hu) Neurotróf faktorok
ATE403680T1 (de) Herstellung tetravalenter antikörper
EA200800094A1 (ru) Антитела cd19 и их использование
MX2009002816A (es) Proteinas de fusion de albumina.
DE60224291D1 (de) System zur antikörperexpression und- synthese
WO2002018620A3 (en) Neutrokine-alpha and neutrokine-alpha splice variant
WO2003033658A3 (en) Neutrokine-alpha and neutrokine-alpha splice variant
CY1109518T1 (el) Αναστολεας ενεργοποιητη αυξητικου παραγοντα ηπατοκυτταρων για χρηση σε διαμορφωση αγγειογενεσης και καρδιοαγγειωσης
ATE299854T1 (de) Chinonverbindungen zur behandlung von krankheiten
ATE431405T1 (de) Tnf-rezeptor-ähnliche moleküle und deren anwendungen
ATE472998T1 (de) Kationische liposomale zubereitungen zur behandlung von rheumatoider arthritis
ATE244014T1 (de) Verwendung von apoptose-induzierende mittel zur herstellung eines mittels zur behandlung von (auto)immunkrankheiten
ATE313561T1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
MXPA03000979A (es) Moleculas tipo receptor de complemento c3b/c4b y usos de las mismas.
MXPA03010728A (es) Moleculas de proteina-2 relacionadas con b7 y uso de las mismas.
ATE479705T1 (de) Reduzierter slam abhängiger zell eintritt
WO2004089982A3 (en) April variants and methods thereof
DE60020970D1 (de) Monoklonaler antikörper mit selektiver bindung an vgf und verwendung zur behandlung von vgf-erkrankungen
EA200600314A1 (ru) Использование растворимого cd164 при воспалительных и/или аутоимунных нарушениях
WO2002072632A3 (en) Nucleic acids of the human abcc11 gene, vectors containing such nucleic acids and uses thereof.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1143994

Country of ref document: EP

REN Ceased due to non-payment of the annual fee